My Blue Dots

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-8520, an investigational oral therapy for the treatment of adult patients with previously treated, KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC). BBO-8520 is designed to i

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

BOSTON–(BUSINESS WIRE)–PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)